Search results
Showing 211 to 225 of 1334 results for long term conditions
This guideline covers the circumstances for inducing labour, methods of induction, assessment, monitoring, pain relief and managing complications. It aims to improve advice and care for pregnant women who are thinking about or having induction of labour.
Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults.
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
meetings. Further guidance The guidance recommends that decisions about long-term care are not made whilst in crisis and...
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (HTG721)
Evidence-based recommendations on endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes. This involves using heat to destroy the lining of the duodenum to encourage a new lining to grow.
View recommendations for HTG721Show all sections
This quality standard covers the recognition, diagnosis and early management of suspected sepsis in people over 16 who are not or have not recently been pregnant. It describes high-quality care in priority areas for improvement.
View quality statements for QS213Show all sections
Sections for QS213
- Quality statements
- Quality statement 1: Assessment in acute settings
- Quality statement 2: Assessment outside acute settings
- Quality statement 3: Urgent assessment and antibiotic treatment for people at high risk
- Quality statement 4: Intravenous fluids
- Quality statement 5: Escalation of care
- Quality statement 6: Information for people whose condition is managed outside acute hospital settings
- Update information
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.
Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.
Naltrexone–bupropion for managing overweight and obesity (TA494)
Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.
Evidence-based recommendations on electroconvulsive therapy (ECT) for treating catatonia, prolonged or severe manic episodes or schizophrenia in adults.
Holoclar for treating limbal stem cell deficiency after eye burns (TA467)
Evidence-based recommendations on Holoclar (a layer of cells grown from cells taken from your own eye) for treating limbal stem cell deficiency in adults with eye burns.
Evidence-based recommendations on encorafenib (Braftovi) plus binimetinib (Mektovi) for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma in adults, when a stem cell transplant is unsuitable.